RxDoctor Payments Data

Harvey Levy

Clinical Biochemical Genetics · Boston, MANPI 1972593150

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $41,357 of the $48,693 with a category attached, or 84.9%. 6 manufacturers reported payments, led by Sanofi US Services Inc. at 33.4% of the total. Reporting peaked in 2023 at $13,385 and has fallen 64.9% since, to $4,700 in 2025.

$48,693in general payments, 2019–2025

Across 47 payments — averaging $1036.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$16K
  • PTC Therapeutics, Inc.$13K
  • Travere Therapeutics, Inc.$11K
  • Agios Pharmaceuticals, Inc.$6K
  • Biomarin Pharmaceutical Inc.$2K
  • Amicus Therapeutics, Inc.$700
$1,874,223in research payments, 2019–2025

Across 60 payments — averaging $31,237 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Travere Therapeutics, Inc.$1.4M
  • Biomarin Pharmaceutical Inc.$483K

What the payments were for

  • Consulting fees$41,35785%
  • Travel & lodging$4,2449%
  • Food & beverage$7902%
  • Education$2,3015%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical biochemical genetics providers in Massachusettsto place this figure against a meaningful peer group, so we don't.

Other clinical biochemical genetics in Boston

Where these figures come from

Is this you, or does something look wrong? →